We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





Clinical Trial to Study Effects of Steroid-Cannabidiol (CBD) Treatment on Hospitalized COVID-19 Patients

By HospiMedica International staff writers
Posted on 02 May 2020
A small-scale clinical trial is currently underway to evaluate the use of Cannabidiol (CBD) for the treatment of hospitalized patients with COVID-19 infection.

The clinical trial is being held by STERO Biotechs Ltd. More...
(Bnei Brak, Israel), a clinical-stage company focused on CBD formulation research and development, in collaboration with Mor Research Applications, the Tech Transfer Office (TTO) of the largest Health Maintenance Organization (HMO) in Israel – Clalit. The small-scale clinical trial is being held at Rabin Medical Center Golda HaSharon Campus, treating 10 patients as a 'POC' with the aim of benefitting and helping hospitalized patients with COVID-19 infection.

Steroid treatment is usually the first or second line of treatment for hospitalized patients. CBD enhances the therapeutic effect of steroid treatment and treats the bio-mechanism affected by the virus. The initial study will evaluate the tolerability, safety, and efficacy of the CBD treatment, for hospitalized patients with COVID-19 infection. The treatment cycle will be for a few weeks with a subsequent follow-up period of the same length. Under Stero's allowed IP and pending the success of the 'POC', the company plans to scale up and expand to a phase 2a multi-center clinical trial, with an additional 40 hospitalized patients with COVID-19 infection, under FDA clinical trial guidelines and regulations.

“We estimate that our CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions,” said David Bassa, Founder & CEO of Stero Biotechs. “Hospitalized COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with steroid treatments. We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”

Related Links:
STERO Biotechs Ltd.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Warming Cabinet
EC1850BL
New
Powered Surgical Stapler
ECHELON 3000 Stapler
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.